← All trials
NCT04364139
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 1995
- Primary completion
- Sep 30, 2001
- Completion date
- Jun 30, 2007
- First posted
- Apr 27, 2020
- Last posted
- Apr 27, 2020
- Enrollment
- 1094
- Arms / groups
- 6 / —
- Source
- AACT · ingestion pipeline
Sponsors
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Lead sponsor
- The Cleveland ClinicCollaborator
- The Cleveland ClinicOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.